Successful Conversion From Parenteral Paricalcitol to Pulse Oral Calcitriol for the Management of Secondary Hyperparathyroidism in Hemodialysis Patients
The management of hyperparathyroidism in hemodialysis patients involves the administration of phosphate binders, vitamin D receptor activators, and calcimimetics. Intravenous paricalcitol has been preferred over oral calcitriol as it may cause less hypercalcemia and hyperphosphatemia. However, there is little data looking at the efficacy and tolerability of oral calcitriol in the calcimimetic era particularly in a real practice-based experience. The University of California, Irvine free-standing dialysis center converted from routine intravenous paricalcitol to oral calcitriol due to pharmacy purchasing preferences.
Conclusions: 99mTc-MIBI SPECT/CT can increase the sensitivity and consistency of preoperative localization of eutopic parathyroid glands, and it can accurately locate ectopic parathyroid without sensitivity improvement. PMID: 31537128 [PubMed - in process]
This article is protected by copyright. All rights reserved. PMID: 31538675 [PubMed - as supplied by publisher]
This article is protected by copyright. All rights reserved.
Normocalcemic primary hyperparathyroidism may be more challenging to cure compared with classical primary hyperparathyroidism. The aim of this study was to utilize a multi-institutional database to better characterize this condition.
AbstractBackgroundSecondary hyperparathyroidism (SHPT) is a common and serious complication of chronic kidney disease, particularly in end-stage renal disease. Currently, both cinacalcet and vitamin D are used to treat SHPT via two different mechanisms, but it is still unclear whether the combination use of these two drugs can be a safe and effective alternative to vitamin D alone. Therefore, the aim of this meta-analysis was to assess the efficacy and safety of cinacalcet plus vitamin D in the treatment of SHPT.MethodsFour electronic databases, including PubMed, EMBASE, Cochrane Central Register of Controlled Trials (CENT...
We present a case of a hybrid lesion of COF and CGCG. The lesion presented as a radiolucent lesion of the left mandible that caused bony expansion and paresthesia. Microscopic examination revealed a florid population of fibrohistiocytic cells and multinucleated giant cells in a densely collagenized fibrous connective matrix. Interspersed among this proliferation, lobular collections of intensely basophilic cells with benign cytologic appearance were observed. Immunohistochemistry staining with MCK, Calretinin, CK5/6, and CD68 separated these islands of odontogenic cells from the surrounding multinucleated giant cells and h...
AbstractIndependently of plasma 25-hydroxyvitamin D (P-25(OH)D) levels, elevated parathyroid hormone (PTH) levels may exert an adverse effect on muscle health, postural stability, well-being, and quality of life. Using a cross-sectional design, we investigated 104 healthy postmenopausal women with low P-25(OH)D ( 6.9 pmol/l,n = 52) or normal PTH levels (n = 52). The average PTH value in women with SHPT was 8.5 (interquartile range 7.5–9.7) pmol/l and 5.3 (4.4–6.3) pmol/l in women with normal PTH (p
Conclusions: Parathyroidectomy in primary hyperparathyroidism during pregnancy is safe. PMID: 31501633 [PubMed - in process]
Conditions: Primary Hyperparathyroidism; Osteoporosis Interventions: Drug: Denosumab 60 MG/ML Prefilled Syringe [Prolia]; Drug: Zoledronic Acid Sponsor: University Medical Centre Ljubljana Recruiting